PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Original Article

N. Agarwal, N. Matsubara, A.A. Azad, F. Saad, J. Mateo, S. Jiang, D. Ye, E. Voog, N.D. Shore, T. Çil, C. Vulsteke, H.-J. Chung, S. Zschäbitz, A.D. Laird, X. Zhang, P. Nandoskar, S.F. Chetcuti, F. Wang, and K. Fizazi

N Engl J Med 2026;395:427-439

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
07/29/2026
Course expires: 
07/30/2028

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.